PQR309 is a novel dual PI3K/mTOR inhibitor with antitumor pre-clinical activity in lymphomas as single agent and in combination
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94670
下载链接
链接失效反馈官方服务：
资源简介：
assess the efficacy of dual PI3K/mTOR inhibitor with anti-lymphoma activity as single agent and in combination GEP analysis of 8 lymphoma cell lines with and without treatment
创建时间：
2019-01-24
